SCHEMBL30051312

SCHEMBL30051312

Cc1cc(N)ccc1Oc1cnc2c(c1)ncn2C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 2/20 0.44
DOT1L Q8TEK3 1/20 0.38
DYRK1A Q13627 1/20 0.35
ERBB2 P04626 4/20 0.34
EGFR P00533 3/20 0.34
MAPT P10636 3/20 0.33
ALDH1A1 P00352 3/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
FGFR1 P11362 1/20 0.33
ERBB3 P21860 1/20 0.33
ERBB4 Q15303 1/20 0.33
KDM4E B2RXH2 3/20 0.33
MEN1 O00255 1/20 0.33
LMNA P02545 1/20 0.33
THRB P10828 1/20 0.33
ALOX15 P16050 1/20 0.33
KMT2A Q03164 1/20 0.33
HSD17B10 Q99714 1/20 0.32
ADORA2A P29274 1/20 0.32
ADORA1 P30542 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23959239 1.00 GRM5 (0.44) GRM5DOT1LDYRK1AERBB2EGFR
SCHEMBL30050677 0.86 GRM5 (0.43) GRM5DOT1LDYRK1AERBB2EGFR
SCHEMBL1191996 0.82 KMT2A (0.46) ERBB2EGFRMAPTALDH1A1SMN1; SMN2
SCHEMBL30050420 0.81 GRM5 (0.42) GRM5DOT1LDYRK1AERBB2
SCHEMBL24807701 0.81 GRM5 (0.42) GRM5DOT1LDYRK1AERBB2
SCHEMBL31257495 0.81 DYRK1A (0.39) GRM5DYRK1AERBB2EGFRMAPT
SCHEMBL24809031 0.80 GRM5 (0.40) GRM5DOT1LDYRK1AADORA2AADORA1
SCHEMBL30050656 0.79 L3MBTL1 (0.46) GRM5MAPTALDH1A1SMN1; SMN2KDM4E
SCHEMBL24807693 0.79 DPP4 (0.34) ERBB2EGFRMAPTALDH1A1SMN1; SMN2
SCHEMBL31693489 0.79 DPP4 (0.34) ERBB2EGFRMAPTALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025202889-A1 HER2 MUTATION INHIBITORS ARRAY BIOPHARMA INC. (US) 2025-10-02 WO disclosed
US-20250129078-A1 ERBB2 INHIBITORS COGENT BIOSCIENCES, INC. 2025-04-24 US disclosed
WO-2022269531-A1 HER2 MUTATION INHIBITORS ARRAY BIOPHARMA INC. (US) 2022-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250129078-A1 ERBB2 INHIBITORS ERBB2, ERBB3, EGFR GRM5 1697/4885DOT1L 1744/4885DYRK1A 24/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.